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Life Course Trajectories of Cardiovascular Risk Factors in Women
With and Without Hypertensive Disorders in First Pregnancy: The
HUNT Study in Norway
Eirin B. Haug, MSc; Julie Horn, MD, PhD; Amanda R. Markovitz, MPH, ScD; Abigail Fraser, MPH, PhD; Lars J. Vatten, MD, PhD;
Corrie Macdonald-Wallis, PhD; Kate Tilling, PhD; Pal R. Romundstad, PhD; Janet W. Rich-Edwards, MPH, ScD; Bjørn O. Asvold, MD, PhD
Background-—Women with hypertensive pregnancy disorders have adverse levels of cardiovascular risk factors. It is unclear how
this adverse risk factor proﬁle evolves during adult life. We compared life course trajectories of cardiovascular risk factors in
women with preeclampsia or gestational hypertension in their ﬁrst pregnancy to normotensive women.
Methods and Results-—We linked information on cardiovascular risk factors from the population-based HUNT (Nord-Trøndelag
Health Study) surveys with pregnancy information from the Medical Birth Registry of Norway. Trajectories of cardiovascular risk
factors were constructed for 22 308 women with a normotensive ﬁrst pregnancy; 1092 with preeclampsia, and 478 with
gestational hypertension in ﬁrst pregnancy. Already before ﬁrst pregnancy, women with preeclampsia in their ﬁrst pregnancy had
higher measures of adiposity, blood pressure, heart rate, and serum lipids and glucose compared with women with a normotensive
ﬁrst pregnancy. After ﬁrst pregnancy, there was a parallel development in cardiovascular risk factor levels, but women with a
normotensive ﬁrst pregnancy had a time lag of >10 years compared with the preeclampsia group. There were no clear differences
in risk factor trajectories between women with gestational hypertension and women with preeclampsia.
Conclusions-—Women with hypertensive pregnancy disorders in their ﬁrst pregnancy had an adverse cardiovascular risk factor
proﬁle before pregnancy compared with normotensive women, and the differences persisted beyond 50 years of age. Hypertensive
disorders in pregnancy signal long-term increases in modiﬁable cardiovascular risk factors, and may be used to identify women
who would beneﬁt from early prevention strategies. ( J Am Heart Assoc. 2018;7:e009250. DOI: 10.1161/JAHA.118.009250.)
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C ardiovascular disease (CVD) accounts for 1 in 3 deathsin women.1 Hypertensive disorders of pregnancy (HDP),
including preeclampsia and gestational hypertension, occur in
up to 10% of all pregnancies.2 Pregnancy may serve as a
stress test of maternal cardiovascular health, where HDP may
indicate a reduced ability to accommodate the extra cardio-
vascular and metabolic challenges of pregnancy.3 HDP may
reveal a phenotype predisposed to CVD, and may therefore be
used to identify women who would beneﬁt from early
screening and preventive efforts. A history of HDP has been
included as a cardiovascular risk factor in CVD prevention
guidelines in the United States since 20114 and in Europe
since 2016.5 Yet there is little evidence and no consensus on
how to tailor CVD screening and prevention in women with a
history of HDP. Although previous studies reported adverse
cardiovascular risk factor proﬁles in women with HDP both
before and after pregnancy,6–17 detailed knowledge on how
different cardiovascular risk factors develop throughout life is
lacking. In particular, it is unclear when in life the elevated
cardiovascular risk proﬁle manifests itself in women with a
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history of HDP, and whether and how this proﬁle may
change from before to after a pregnancy complicated with
HDP, and also how differences in cardiovascular risk factors
between women with and without HDP may evolve
postpartum.
To our knowledge, no longitudinal studies have examined
long-term trajectories of cardiovascular risk factors among
women with a history of HDP from before ﬁrst pregnancy until
middle age. In the HUNT (Nord-Trøndelag Health Study)
cohort in Norway, we recently observed that higher blood
pressure in women with a history of HDP manifests before
ﬁrst pregnancy and lasts beyond 60 years of age.18 In the
present study, we examine the life course trajectories from
before ﬁrst pregnancy and until 60 years of age for a broad
range of cardiovascular risk factors in women with and
without HDP in their ﬁrst pregnancy.
Methods
Data from the HUNT Study used in research projects will
when reasonably requested by others be made available
upon request to the HUNT Data Access Committee
(hunt@medisin.ntnu.no). The HUNT data access informa-
tion (available here: http://www.ntnu.edu/hunt/data)
describes in detail the policy regarding data availability.
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amendments
or comparable ethical standards. Informed consent was
obtained from all individual participants included in the study.
Study Population
The HUNT study is a longitudinal population study that has
invited all adult inhabitants 20 years and older in Nord-
Trøndelag county, Norway, to take part in health surveys since
the 1980s. The surveys include questionnaires, interviews,
blood sampling, and clinical measurements.19–21 So far, 3
HUNT surveys have been conducted: HUNT1 1984–1986,20
HUNT2 1995–1997,21 and HUNT3 2006–2008.19 The pre-
dominantly (>97% at the time of HUNT2) white population in
Nord-Trøndelag is considered to be fairly representative for
Norway as a whole.21 The Medical Birth Registry of Norway
(MBRN) has recorded all births in the country since 1967 and
provides detailed information on maternal and child
characteristics.22 Information from the MBRN and HUNT
was linked using the 11-digit unique personal identiﬁcation
number that is allocated to all Norwegian citizens. In total,
25 932 women whose ﬁrst delivery had been recorded in the
MBRN between its inception in 1967 and 2012 had also taken
part in at least 1 HUNT survey between 1984 and 2008.
Among them, we excluded 314 women whose ﬁrst birth was a
multiple and, since preeclampsia and gestational hyperten-
sion cannot be diagnosed before 20 weeks of gestation, we
further excluded 56 women with either gestational length
<20 weeks, offspring birth weight <350 g, or missing
information on both gestational length and offspring birth
weight. In addition, we excluded 88 women who had a pre-
ﬁrst pregnancy diagnosis of hypertension and 357 women
who were pregnant or <3 months postpartum at all their
HUNT examinations. Lastly, we excluded 1239 women
because of incomplete information on smoking or education
or because they had no cardiovascular risk factor measure-
ments, leaving 23 878 women for statistical analysis
(Figure 1).
Exposures and Covariates
Diagnoses of preeclampsia and gestational hypertension in
ﬁrst pregnancy were retrieved from the MBRN, which uses
internationally recommended diagnostic criteria2: Gestational
hypertension was generally deﬁned as de novo hypertension
(≥140 mm Hg systolic and/or ≥90 mm Hg diastolic) after
20 weeks of gestation, and preeclampsia also required
proteinuria (300 mg/24 h or ≥1+ on the dipstick test).
Validation studies23,24 within the HUNT study population have
estimated the positive predictive values of the preeclampsia
and gestational hypertension diagnoses in the MBRN to be
88% and 68%, respectively.
Clinical Perspective
What Is New?
• In women with hypertensive disorders of pregnancy (HDP),
adverse levels of adiposity, blood pressure, heart rate,
serum lipids and glucose were present before ﬁrst preg-
nancy and remained higher compared with other women
beyond 50 years of age.
• Progression of cardiovascular risk factors throughout the
age interval 20 to 60 years occurred mostly in parallel for
women with and without a history of HDP, with greater
increases in systolic blood pressure and adiposity in women
with a history of HDP.
What Are the Clinical Implications?
• Women with a history of HDP may be expected to pass
beyond treatment thresholds of cardiovascular risk factors
at least 10 years earlier than women with normotensive
pregnancy.
• Our results suggest that women with a history of HDP may
beneﬁt from early screening and intervention programs that
seek to lower the levels of cardiovascular risk factors.
DOI: 10.1161/JAHA.118.009250 Journal of the American Heart Association 2
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From the HUNT questionnaires and interviews, we
retrieved self-reported information on use of antihypertensive
medication, diabetes mellitus, ever daily smoking, hours since
last meal, highest obtained educational level, and work titles.
Since education level was not available in HUNT3, we derived
educational level from work titles based on recommendations
from Statistics Norway25 for 5546 women.
Cardiovascular Risk Factors
Blood sampling and clinical measurements were performed by
trained staff at the HUNT examination stations. Height and
weight were measured with the person wearing light clothes
and no shoes and were rounded to the nearest cm (height)
and half kilo (weight). Body mass index (BMI) was calculated
as weight (in kg) divided by the squared value of height (in m),
and obesity was deﬁned as BMI ≥30 kg/m2. For 12 832
women in HUNT3, we also calculated BMI at age 18 years
using self-reported height and weight at age 18 years. Blood
pressure in HUNT1 was measured manually 2 times at 1-
minute intervals using a sphygmomanometer after the person
had come to rest, and we used the mean value of these 2
measurements in our analysis. In HUNT2 and HUNT3, blood
pressure was measured 3 times at 1-minute intervals using an
automatic oscillometric method (Dinamap, Critikon, FL) after
the person had come to rest, with cuff size adjusted to arm
circumference. We used the mean of the second and third
measurement, except for 2135 women in HUNT3 who lacked
the third measurement because of sick leave among staff; for
them, we used the second measurement only. Based on
recommendations by Cui et al26 and Tobin et al,27 we added
10 mm Hg to systolic and 5 mm Hg to diastolic blood
Figure 1. Flow chart of study population. HUNT indicates Nord-Trøndelag Health Study.
DOI: 10.1161/JAHA.118.009250 Journal of the American Heart Association 3


















 http://ahajournals.org by on September 17, 2018
pressure levels for 2137 women who reported taking
antihypertensive medication. We classiﬁed women as having
hypertension if they reported taking antihypertensive medi-
cation, or whose blood pressure was either ≥140 mm Hg
systolic or ≥90 mm Hg diastolic. Resting heart rate in beats/
min was measured 1 time in HUNT1 and 3 times in HUNT2
and HUNT3 using the same devices as for blood pressure
described above. For HUNT2 and HUNT3, we used the mean
of the second and third measurements. Waist and hip
circumference (available in HUNT2 and HUNT3) were mea-
sured to the nearest centimeter while the person was
standing with arms hanging down at the height of the
umbilicus (waist circumference) or at the thickest part of the
hip (hip circumference).
All serum analyses were performed in nonfasting samples
at the Central Laboratory, Levanger Hospital, Nord-Trøndelag
Hospital Trust using a Hitachi 911 Autoanalyzer in HUNT2 and
Architect cSystems ci8200 in HUNT3. All analyses were
performed in fresh serum samples, except C-reactive protein
(CRP) in HUNT2, which was measured after 2 years of serum
storage at 80°C. Serum total and high-density lipoprotein
(HDL) cholesterol and triglycerides were analyzed using
enzymatic colorimetric methods (Boeheringer Mannheim,
Germany) in HUNT2. In HUNT3, HDL cholesterol was
measured with an accelerator selective detergent methodol-
ogy, total cholesterol was analyzed by a cholesterol esterase
methodology, and triglycerides were measured by a glycerol
phosphate oxidase methodology, all by equipment from
Abbott, Clinical Chemistry, USA. Non-HDL cholesterol was
calculated as the difference between total and HDL choles-
terol. High-sensitive CRP was measured in participants from 4
out of 24 municipalities (n=2766) in HUNT2 using a CRP
ultrasensitive assay (Tina-quant(R); Roche, Basel, Switzerland).
In HUNT3, CRP was measured in everyone using a latex
immunoassay (Abbott, Clinical Chemistry, USA). In HUNT2
and HUNT3, serum glucose was measured for all persons
using an enzymatic hexokinase method. In HUNT1, capillary
glucose was measured at the examination stations in
participants >40 years (Reﬂocheck-Glucose; Boehringer Man-
nheim, Germany), and for the analysis of mean glucose levels,
we transformed capillary levels to equate serum values (in
mmol/L) by multiplying by 1.11.28 In HUNT1, fasting capillary
glucose was measured in persons with capillary glucose
≥8.0 mmol/L at the initial examination, and a 2-hour oral
glucose tolerance test was given if fasting capillary glucose
was <7.0 mmol/L. If capillary glucose concentrations indi-
cated diabetes mellitus (≥7.0 mmol/L fasting or
≥11.1 mmol/L after 2 hours), the corresponding serum
glucose concentrations were measured. We deﬁned diabetes
mellitus by self-report (all HUNT surveys), nonfasting serum
glucose ≥11.1 mmol/L (HUNT2 or HUNT3), or fasting serum
glucose ≥7.0 mmol/L or 2-hour postload serum glucose
≥11.1 mmol/L (HUNT1). Serum creatinine was measured
with the Jaffe method in HUNT2 (Roche Diagnostics,
Mannheim, Germany) and with an alkaline picrate methodol-
ogy in HUNT3 (Abbott, Clinical Chemistry, USA), and
calibrated to isotope-dilution mass-spectroscopy level using
an enzymatic method (Roche).29 Estimated glomerular ﬁltra-
tion rate in mL/min per 1.73 m2 was calculated using the
Chronic Kidney Disease Epidemiology consortium formula,30
which takes account of creatinine, age, and sex.
Statistical Analysis
Life course trajectories of cardiovascular risk factors were
modeled using linear spline mixed-effects models,31 except
for CRP, which had a limited number of repeated measure-
ments and was modeled using a linear spline regression
model with a cluster-robust estimate of variance (Huber/
White sandwich estimate). The linear spline mixed-effects
models included subject-speciﬁc (random) intercepts and
slopes to account for up to 3 repeated dependent observa-
tions per woman and facilitated estimation of within-woman
trajectories.32 Linear splines deﬁned by age intervals were
used in order to allow for nonlinear change in the
cardiovascular risk factor over time. The most appropriate
age intervals were determined for each cardiovascular risk
factor by comparing performance of models with 2, 4, 5, 6,
8, and 10 years age intervals using the Bayesian Information
Criterion. On the basis of this, 10-year age intervals up to
age 70 years were selected for all cardiovascular risk
factors. All models adjusted for highest obtained education
level (lower secondary [≤9 years], upper secondary [10–
12 years], and tertiary [college or university]), ever daily
smoking, HUNT survey, and age at ﬁrst birth while also
allowing the age-dependent change in cardiovascular risk
factor (linear spline) to vary by exposure status and by
different levels of these potential confounders. Analyses of
glucose and triglycerides were additionally adjusted for
number of hours since last meal (<1, 1, 2, 3, 4, 5, or
≥6 hours). We included 1 term describing the immediate
change in cardiovascular risk factor level from pre- to post-
ﬁrst pregnancy, and another indicating the change in
increase/decrease per year (slope) from pre- to post-ﬁrst
pregnancy. We allowed both terms to vary by whether the
woman’s ﬁrst pregnancy was complicated by preeclampsia/
gestational hypertension or was normotensive and by
different levels of education, smoking, and age at ﬁrst birth.
All women aged 20 to 82 years old were included in the
analysis, but because of limited data for women >60 years,
we show predicted cardiovascular risk factor trajectories for
the age range 20 to 60 years (18–60 for BMI, because of
the available self-reported height and weight at age 18
years). We had insufﬁcient data to model the risk factor
DOI: 10.1161/JAHA.118.009250 Journal of the American Heart Association 4
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trajectories during pregnancy and placed gaps in the
predicted trajectories corresponding to the ﬁrst pregnancy
and a 3 months postpartum period. We predicted the risk
factor trajectories as if the woman had her ﬁrst birth at age
23 years, the median age at ﬁrst birth in our study
population, and with all the remaining covariates set at their
sample means. As a sensitivity analysis, we also modeled the
same cardiovascular risk factor trajectories among women
who had taken part in 2 or more HUNT surveys in order to
examine the potential impact of including women with single
measurements. In a separate analysis using logistic regres-
sion with cluster-robust variance, we also estimated the
probability of being obese, having hypertension or diabetes
mellitus as a function of age adjusting for highest obtained
education level, ever daily smoking, age at ﬁrst birth, and
HUNT survey. In an additional analysis among women with at
least 2 pregnancies, we examined whether repeat
preeclampsia was associated with a more adverse cardio-
vascular risk proﬁle. In this analysis, we contrasted cardio-
vascular risk trajectories in women having preeclampsia in
both ﬁrst and second pregnancy with women having
preeclampsia in one of these pregnancies. Since the risk
of preeclampsia is associated with pregnancy interval,33,34
we additionally adjusted for time between the ﬁrst and
second pregnancy in this analysis. All analyses were
performed using Stata IC 14 and MLwiN version 2.3435 via
the runmlwin36 command in Stata.
Results
Characteristics of our study population are given in the Table.
Among 23 878 women, 1092 (5%) had preeclampsia and 478
(2%) had gestational hypertension in their ﬁrst pregnancy.
Cardiovascular risk factors were measured within a time span
of 20 years before to 40 years after ﬁrst birth. In total, 7273
(30%) women participated in all 3 HUNT surveys, 7248 (30%)
took part in 2 and 9357 (39%) only participated in 1 HUNT
survey. Median age at ﬁrst birth was similar for women with
preeclampsia, gestational hypertension, and normotension in
ﬁrst pregnancy. Preterm delivery and small for gestational age
offspring were more common in preeclamptic pregnancies.
The numbers of women and measurements included in each
of the cardiovascular risk factor analyses are given in
Table S1, and Figure S1 displays the distribution of observa-
tions by participation age and HUNT survey.
For the sake of clarity and brevity, we focus the description
of the results on risk factor trajectories in women with
preeclampsia compared with normotension in ﬁrst pregnancy.
However, throughout the analyses, results for women with
gestational hypertension in ﬁrst pregnancy were comparable
to those for women with preeclampsia; full results for
gestational hypertension are given in Figures S2 and S3.
Where no reference to the order of the pregnancy is made, it
is implied that we mean the ﬁrst pregnancy.
At the age of 20 years, women who later had a
preeclamptic pregnancy had 5.2 mm Hg (95% conﬁdence
interval [CI], 3.2–7.2) higher systolic and 3.5 mm Hg (95% CI,
2.0–5.0) higher diastolic blood pressure compared with
women who later had a normotensive pregnancy (Figure 2A
and 2B, Table S2). From pre- to postpregnancy, systolic blood
pressure decreased both in women with preeclampsia and
normotensive pregnancies, whereas diastolic blood pressure
decreased only in women with normotensive pregnancies
(Table S3). In the years following pregnancy, the increase in
blood pressure was similar among women with preeclampsia
and normotensive pregnancy, except that women with
preeclampsia had a steeper increase in systolic blood
pressure from 40 to 50 years of age (Table S4). By age 60
years, systolic blood pressure was 9.0 mm Hg (95% CI, 6.2–
11.8) higher and diastolic blood pressure was 2.8 mm Hg
(95% CI, 1.0–4.6) higher in women with preeclampsia
compared with normotensive pregnancy (Table S2). The
prevalence of hypertension was higher in women with
preeclampsia compared with normotensive pregnancy
throughout the entire age range, and the prevalence in
women with preeclampsia increased more strongly after age
30 years, a decade earlier than the corresponding increase
among women with normotensive pregnancy (Figure 3A,
Table S5). At age 60 years, 78% (95% CI, 70–84) of women
with a ﬁrst preeclamptic pregnancy had hypertension, com-
pared with 58% (95% CI, 55–60) of women with normotensive
pregnancy (Figure 3A, Table S5).
BMI was 1.1 kg/m2 (95% CI, 0.8–1.3) higher at age 20
years in women with subsequent preeclampsia compared with
women with a normotensive pregnancy (Figure 2C, Table S2).
Up to pregnancy, and from pre- to immediately postpreg-
nancy, BMI increased more steeply among women with
preeclampsia (Tables S3 and S4). In the years after
pregnancy, BMI increased linearly and in parallel in both
groups, and at age 60 years, BMI was 2.4 kg/m2 (95% CI,
1.8–3.0) higher among women with preeclampsia compared
to women with a normotensive pregnancy (Table S2). By age
60 years, the prevalence of obesity was 18% (95% CI, 12–24)
in women with preeclampsia and 11% (95% CI, 10–13) in
women with a normotensive pregnancy (Figure 3B and
Table S5). Waist circumference and waist-to-hip ratio, mea-
sures of abdominal adiposity, were also consistently higher in
women with a preeclampsia pregnancy, and increased with
age in a broadly parallel fashion in both groups (Figure 2D
through 2F, Tables S2 and S4).
Non-HDL cholesterol was 0.24 mmol/L (95% CI, 0.05–
0.43) higher at age 20 years among women with subsequent
preeclampsia compared with a normotensive ﬁrst pregnancy
(Figure 4A, Table S2), and increased similarly in both groups
DOI: 10.1161/JAHA.118.009250 Journal of the American Heart Association 5
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until age 40 years (Figure 4A, Table S4). From 40 to 60 years,
women with a normotensive pregnancy had a seemingly
steeper rise, resulting in the 2 groups of women having similar
non-HDL cholesterol levels by age 60 years (Figure 4A,
Table S2). HDL cholesterol levels were similar between the
groups prepregnancy (Figure 4B, Table S2) and immediately
postpregnancy. Women with preeclampsia then had lower
HDL cholesterol until beyond 50 years of age compared with
women with normotensive pregnancy (Figure 4B, Table S2).
Triglyceride levels were 0.18 mmol/L (95% CI, 0.05–0.32)
Table. Descriptive Characteristics of the Study Population
Hypertension Status of First Pregnancy
Normotension (n=22 308) Gestational Hypertension (n=478) Preeclampsia (n=1092)
Maternal characteristics
Birth year, median (IQR) 1959 (1951–1968) 1957 (1951–1966) 1962 (1953–1970)
Age at first birth, median (IQR) 23 (20–26) 24 (21–27) 24 (21–27)
Ever daily smoking, n (%)
No 9132 (41) 240 (50) 585 (54)
Yes 13 176 (59) 238 (50) 507 (46)
Education, n (%)
Lower secondary (≤9 y) 3737 (17) 89 (19) 177 (16)
Upper secondary (10–12 y) 10 540 (47) 217 (45) 551 (50)
Tertiary (>12 y) 8031 (36) 172 (36) 364 (33)
Ever use of antihypertensive medication, n (%)
No 20 271 (91) 332 (69) 775 (71)
Yes 2033 (9) 146 (31) 317 (29)
Missing 4 (0) 0 (0) 0 (0)
Age at first HUNT exam, median (IQR) 31 (26–37) 31 (26–37) 31 (26–36)
No. of HUNT exams, n (%)
1 8701 (39) 177 (37) 479 (44)
2 6799 (30) 125 (26) 324 (30)
3 6808 (31) 176 (37) 289 (26)
HUNT exams relative to first pregnancy, n (%)
Before first pregnancy only 1927 (9) 50 (10) 113 (10)
After first pregnancy only 18 166 (81) 380 (79) 847 (78)
Before and after first pregnancy 2215 (10) 48 (10) 132 (12)
First pregnancy characteristics
Gestational length in wks, n (%)
<34 407 (2) 4 (1) 57 (5)
34–36 753 (3) 11 (2) 106 (10)
≥37 20 033 (90) 439 (92) 857 (78)
Missing 1115 (5) 24 (5) 72 (7)
Birth weight, n (%)*
Small for gestational age 658 (3) 23 (5) 118 (11)
Normal 19 952 (89) 424 (89) 876 (80)
Large for gestational age 399 (2) 5 (1) 19 (2)
Missing 1299 (6) 26 (5) 79 (7)
Stillbirths, n (%) 193 (1) 2 (0) 21 (2)
IQR indicates interquartile range; HUNT, Nord-Trøndelag Health Study.
*Small and large for gestational age were deﬁned as >2 standard deviations away from the established mean birth weights by gestational age in the Medical Birth Registry of Norway.37
DOI: 10.1161/JAHA.118.009250 Journal of the American Heart Association 6
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higher at age 20 in women who later had preeclampsia
compared with normotensive pregnancy (Figure 4C,
Table S2), and this difference between the groups remained
broadly unchanged until 50 years of age. At age 60 years, the
2 groups of women had similar levels of all lipid subtypes
(Figure 4A through 4C, Table S2).
Figure 2. Life course trajectories of mean systolic blood pressure (A), diastolic blood pressure (B), BMI (C), waist circumference (D),
hip circumference (E), and waist-to-hip ratio (F) for women with normotensive and preeclamptic ﬁrst pregnancies. Estimates are
adjusted for age at measurement, HUNT survey, highest obtained education level, age at ﬁrst birth, and ever daily smoking. Covariates
are ﬁxed at their means with gaps in the graphs corresponding to the woman’s ﬁrst pregnancy, birth at age 23 years, and a 3-month
postpartum period. BMI indicates body mass index; CI, conﬁdence interval; HUNT, Nord-Trøndelag Health Study.
DOI: 10.1161/JAHA.118.009250 Journal of the American Heart Association 7
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Nonfasting serum glucose was 0.2 mmol/L higher in
women with preeclampsia compared with normotensive
pregnancies (Figure 4D, Table S2), and this difference was
similar from ages 20 to 60 years. Diabetes mellitus preva-
lence rose faster in women with preeclampsia compared with
normotensive pregnancy (Figure 3C). At age 60 years, 6%
(95% CI, 3–12) of women with preeclampsia and 3% (95% CI,
2–4) of women with normotensive ﬁrst pregnancies had
diabetes mellitus (Table S5).
Resting heart rate was 2.4 beats/min (95% CI, 0.4–4.3)
faster at age 20 in women with preeclampsia compared with
normotensive pregnancy (Figure 4E, Table S2). After preg-
nancy, resting heart rate was 1 beat/min faster until
50 years of age in women with preeclampsia compared with
normotensive pregnancy (Table S2). Prepregnancy CRP levels
were similar in women with preeclampsia and normotensive
pregnancy (Figure 4F, Table S2). Following pregnancy, CRP
was higher in preeclamptic women, especially at age 30 to 55
years, but the CRP trajectories were less precise because of a
lower number of measurements (Figure 4F, Table S2). Esti-
mated glomerular ﬁltration rate decreased in a linear fashion
throughout the entire age-interval in all women without any
noticeable differences between women with normotension or
preeclampsia in their ﬁrst pregnancy (Figure S4).
For all the above-described analyses except for CRP, we
obtained similar results when restricting the analysis to women
with 2 or more repeated measures (Figures S5 and S6).
The analysis of repeat exposure to preeclampsia included
121 women with preeclampsia in both ﬁrst and second
pregnancy, 929 women with preeclampsia in 1 of these
pregnancies, and 18 577 women who were normotensive in
both ﬁrst and second pregnancy. Women with repeat
preeclampsia had higher systolic and diastolic blood pressure,
increased risk of hypertension and higher BMI, waist circum-
ference, and serum glucose in midlife compared with women
with only 1 occurrence of preeclampsia (Figures S7 through
S10). Women with repeat preeclampsia also tended to have
more adverse levels of all other cardiovascular risk factors
except estimated glomerular ﬁltration rate, but the low
number of women with repeat preeclampsia precluded
precise estimates. Life course trajectory of diabetes mellitus
prevalence among women with repeat preeclampsia could not
be estimated because of too few events.
Discussion
In this longitudinal population-based study, multiple cardio-
vascular risk factors were already elevated before ﬁrst
pregnancy in women who later experienced HDP compared
with women with normotensive ﬁrst pregnancies. Risk factor
trajectories of women with HDP and normotensive ﬁrst
pregnancy displayed a roughly parallel pattern after preg-
nancy, but the increases in systolic blood pressure and
measures of adiposity from 20 to 60 years of age were
somewhat steeper among women with HDP. Although levels
Figure 3. Population average predicted probabilities of
hypertension (deﬁned as current antihypertensive medication
and/or blood pressure ≥140 mm Hg systolic or ≥90 mm Hg
diastolic) (A), obesity (deﬁned as a BMI ≥30 kg/m2) (B), and
diabetes mellitus (deﬁned as self-reported diabetes mellitus,
nonfasting serum glucose ≥11.1 mmol/L, fasting serum
glucose ≥7.0 mmol/L, and/or 2-hour postload serum glucose
≥11.1 mmol/L) (C) by age in women with normotensive and
preeclamptic ﬁrst pregnancies. Estimates are adjusted for age
at measurement, HUNT survey, highest obtained education
level, age at ﬁrst birth, and ever daily smoking. Covariates are
ﬁxed at their means with gaps in the graphs corresponding to
the woman’s ﬁrst pregnancy, birth at age 23, and a 3-month
postpartum period. BMI indicates body mass index; CI,
conﬁdence interval; HUNT, Nord-Trøndelag Health Study.
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Figure 4. Life course trajectories of mean nonfasting serum non-HDL (A) and HDL (B) cholesterol, triglycerides (C), and glucose (D), resting
heart rate (E), and serum CRP (F) for women with normotensive and preeclamptic ﬁrst pregnancies. Estimates are adjusted for age at
measurement, HUNT survey highest obtained education level, age at ﬁrst birth and ever daily smoking. Analyses of glucose and triglycerides
were additionally adjusted for time since last meal. Covariates are ﬁxed at their means with gaps in the graphs corresponding to the woman’s
ﬁrst pregnancy, birth at age 23, and a 3-month postpartum period. CRP is given as geometric mean. CI indicates conﬁdence interval; CRP, C-
reactive protein; HDL, high-density lipoprotein; HUNT, Nord-Trøndelag Health Study.
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of blood pressure, adiposity, serum lipids, and glucose
increased with age in both groups of women, there was a
time lag of 10 years or more between mean levels observed
among women with a history of HDP and women with
normotensive ﬁrst pregnancies. The time-related cardiovas-
cular risk proﬁles were similar in women with preeclampsia
and gestational hypertension. Women with repeat preeclamp-
sia in their ﬁrst and second pregnancy had a more adverse
cardiovascular risk factor proﬁle than women with only 1
occurrence of preeclampsia in their ﬁrst 2 pregnancies.
In our previous analysis on parity and life course blood
pressure trajectories from this cohort, we observed that
women with HDP as a group had higher blood pressure from
before ﬁrst pregnancy until beyond 60 years of age.18 In the
present study, we examined a wide range of cardiovascular
risk factors separately among women with preeclampsia and
gestational hypertension. We are not aware of other studies
that have constructed and contrasted life course trajectories
of common cardiovascular risk factors in women with a
history of HDP and women with normotensive pregnancies.
Our work builds on previous studies by Magnussen et al, who
examined the associations between pre- and postpregnancy
cardiovascular risk factors and HDP; however, those studies
were restricted to data from the HUNT1 and HUNTT2
surveys.6,9,38
Our results were generally consistent with previous studies
in showing that women with HDP had adverse levels of
cardiovascular risk factors at various time points from before
ﬁrst pregnancy and until menopause,6–17 with correspond-
ingly increased risks of hypertension, obesity, and diabetes
mellitus.13–15,39–42 Our study adds to the limited evidence
beyond age 50 years, conﬁrming that except for lipids, for
which trajectories converge by age 60 years, other differ-
ences in cardiovascular risk factors persist until age 60 years.
Our ﬁndings also support the theoretical cardiovascular risk
factor trajectories in women with HDP proposed by Sattar and
Greer,3 giving credence to the concept of pregnancy as a
stress test of cardiometabolic function. Additionally, the
observation that most cardiovascular risk factors increase
nearly monotonically with advancing age in women is also
consistent with previous life course trajectory studies on
selected cardiovascular risk factors.43
We were able to describe risk factor trajectories in
normotensive and HDP women with high precision and with
a longer follow-up than previous studies, by applying mixed-
effects models.32 The use of repeated observations of
cardiovascular risk factors pre- and post–ﬁrst pregnancy was
one of the major advantages of our study over previous ones,
enabling the estimation of within-woman trajectories and
hence the ability to assess when higher levels of cardiovas-
cular risk factors in HDP women were present. Our sensitivity
analyses among women with 2 or more observations only
conﬁrmed that the trajectories including the full sample can be
interpreted as within-woman life course trajectories.
Our aim was to describe and contrast life course trajec-
tories of cardiovascular risk factors in order to inform CVD
screening and ultimately prevention in women with HDP. For
that purpose, confounder adjustment was less relevant
compared with studies aiming to examine the causal asso-
ciation of cardiovascular risk factors with HDP. Nevertheless,
we adjusted for educational level and smoking, which are well
established and easily identiﬁed prepregnancy factors poten-
tially part of a common cause of HDP and cardiovascular risk
factor elevation. Prepregnancy BMI may also be part of this
common cause, but incomplete information prevented us
from examining the impact of prepregnancy BMI on the life
course trajectories. We adjusted for age and HUNT survey
occasion, which should reduce the potential impact that
secular trends in blood pressure,44 BMI,45 waist circumference,46
and cholesterol47 during our study period may have had on
the observed difference between HDP and normotensive
women. Antihypertensive treatment was used more frequently
in women with a history of HDP, and although we attempted
to remedy this by adding constants to the observed blood
pressure measurements, as recommended by Cui et al26 and
Tobin et al,27 antihypertensive use could have lowered blood
pressure in HDP more than in normotensive women and
attenuated the estimated difference between the groups. The
use of statin treatment has increased substantially in Norway
starting in the late 1990s48 and could have lowered non-HDL
cholesterol levels in women attending HUNT3 (2006–2008).
In a similar way, the use of b-blockers could have lowered the
resting heart rate of women with HDP to a larger extent than
for women without HDP. This may have contributed to the
smaller differences in non-HDL cholesterol levels and resting
heart rate between HDP and normotensive women who we
observed after 50 years of age, when statin and b-blocker use
is more frequent.
Participation declined in the more recent HUNT surveys
and was lower among people with lower socioeconomic
status and certain adverse health outcomes. However, the use
of antihypertensive medication was similar in participants and
nonparticipants,49 and nonparticipants had lower BMI than
participants.49 It also seems unlikely that participation was
related to HDP. For these reasons we do not expect
nonparticipation to have violated the missing at random
assumption implicit in mixed effects models nor caused
substantial bias in the differences in cardiovascular risk
factors between normotensive and HDP women. The MBRN
provided accurate information on the reproductive histories,
and the validity of the preeclampsia diagnosis within this
population was generally good with a positive predictive value
of 88%.23 For gestational hypertension, the positive predictive
value was 68%, but most women with an MBRN diagnosis of
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gestational hypertension had evidence of either gestational
hypertension or preeclampsia in medical records.23
The absence of noticeable differences between cardiovas-
cular risk factor proﬁles in women with preeclampsia and
gestational hypertension could in part be explained by most
(84%) of the women diagnosed with preeclampsia having a mild
form, as indicated by term delivery (gestational length
≥37 weeks). We did not have a sufﬁcient number of women
with preterm preeclampsia to examine whether this form of
preeclampsia was associated with different cardiovascular risk
trajectories. A validation study23 conducted within the same
cohort also noted that somewomen diagnosed with gestational
hypertension displayed signs of preeclampsia (ie, proteinuria), a
ﬁnding that indicates overlap between the 2 groups of women.
Our and others’ observations that women with subsequent
HDP have adverse cardiovascular risk factors in young adult
life, before ﬁrst pregnancy, support the hypothesis that
adverse cardiovascular risk proﬁles observed in women with
HDP originate early in life. These ﬁndings could be consistent
with a genetic origin of HDP, but while the familial clustering of
preeclampsia is well documented,50 there is limited knowledge
about a possible genetic basis for the disorder.51 The higher
risk of HDP in women who were born prematurely or with low
birthweight52 supports that the elevated cardiovascular risk
factor levels in women with HDP may be attributed to genes or
to adverse in utero conditions.53 Alternatively, women who go
on to develop HDP may have different dietary and lifestyle
patterns in childhood and adolescence that set them on a
divergent adult cardiovascular risk factor trajectory.
Although women with subsequent HDP have an adverse
cardiovascular risk factor proﬁle even before ﬁrst pregnancy,
this does not exclude an additional causal contribution by
HDP.3 However, pre- to postpregnancy changes in most
cardiovascular risk factors were similar between women with
HDP and normotensive women, suggesting that HDP itself did
not contribute to the adverse levels of these risk factors. The
observation that BMI increased more in pregnancies with HDP
is consistent with previous ﬁndings of increased risk of HDP
with higher gestational weight gain,54 but it does not imply
that HDP necessarily caused the higher pre- to postpregnancy
increase in BMI.
As expected from the higher BMI, blood pressure, and
glucose levels in women with HDP, the prevalence of obesity,
hypertension, and diabetes mellitus remained elevated in
women with HDP compared with women with normotensive
pregnancies for the entire age range of 20 to 60 years. From a
clinical perspective, it may be interesting to note that the
probability of hypertension in preeclamptic women started
increasing more rapidly at around age 30, approximately a
decade earlier than in normotensive women, creating a time lag
in the prevalence of hypertension of around 10 years. Obesity,
hypertension, and diabetes mellitus are well known to increase
the risk of CVD.55 Given the substantial body of evidence
showing higher levels of cardiovascular risk factors in women
with HDP, it is highly likely that a substantial proportion of the
excess CVD risk in women with HDP56 is mediated through
these traditional cardiovascular risk factors.
Research suggests that a reduction of 2 mm Hg in diastolic
blood pressure could reduce the risk of coronary heart disease
by 6% and the risk of stroke and transient ischemic attacks by
15%.57 Even such small reductions in blood pressure as that
obtainable by lifestyle modiﬁcation programs could be beneﬁ-
cial in women with a history of HDP. As the adverse cardiovas-
cular risk proﬁle in womenwith a history of HDP inmost cases is
already established in early adulthood, our ﬁndings suggest that
HDP may be included in early CVD screening, and that women
with HDP may particularly beneﬁt from early lifestyle modiﬁca-
tion programs that target cardiometabolic risk factors following
a pregnancy complicated by HDP.
Conclusion
This longitudinal population-based study shows that the
adverse cardiovascular risk factor proﬁles in women with
HDP are present before ﬁrst pregnancy and remain higher
compared with other women beyond 50 years of age.
Progression of cardiovascular risk factors throughout the age
interval 20 to 60 years occurs mostly in parallel for women
with and without a history of HDP, with greater increases in
systolic blood pressure and adiposity in women with a history
of HDP. Women with a history of HDP may be expected to pass
beyond treatment thresholds of blood pressure, adiposity,
serum lipids, and glucose at least 10 years earlier than women
with normotensive pregnancy. HDP signals long-term
increases in modiﬁable cardiovascular risk factors that may
warrant early screening and preventive efforts.
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Table S1. Number of women and measurements included in analysis by CVD risk factor.  
CVD risk factor 
Number of women   Number of measurements 
Normotension  Preeclampsia Gestational 
hypertension   
Normotension  Preeclampsia Gestational 
hypertension 
Systolic blood pressure 22 061 1077 474  42 357 1976 947 
Diastolic blood pressure 22 061 1077 474  42 356 1976 947 
BMI 22 298 1091 478  54 422 2519 1177 
Waist circumference 20 409 1009 433  31 361 1510 678 
Hip circumference 20 410 1009 433  31 362 1510 678 
Waist to hip ratio 20 409 1009 433  31 360 1510 678 
Non-HDL cholesterol 20 283 1007 432  30 977 1493 668 
HDL cholesterol 20 283 1007 432  30 977 1493 668 
Triglycerides 19 858 977 427  30 715 1470 666 
Glucose 19 836 983 429  31 156 1510 683 
Resting heart rate 21 530 1049 467  40 406 1875 895 
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*Linear predictions are estimated with all covariates set at their means and as if the woman has her first birth at age 23. 
Table S2. Predicted mean levels of cardiovascular disease risk factors by age at follow-up in women with normotensive 
and preeclamptic first pregnancies.  
  Normotensive   Preeclampsia   Difference 
Linear prediction* estimate 95% CI   estimate 95% CI   estimate 95% CI p-value 
Systolic blood 
pressure (mmHg)          
20 years 119.03 [118.33 ‒ 119.73]  124.23 [122.21 ‒ 126.24]  5.20 [3.20 ‒ 7.20] <0.001 
1st birth occurs at age 23 
30 years 116.95 [116.62 ‒ 117.29]  123.10 [121.78 ‒ 124.42]  6.15 [4.81 ‒ 7.48] <0.001 
40 years 121.08 [120.79 ‒ 121.38]   127.20 [125.85 ‒ 128.56]   6.12 [4.74 ‒ 7.50]  <0.001 
50 years 129.32 [128.91 ‒ 129.72]  138.69 [136.90 ‒ 140.49]  9.38 [7.55 ‒ 11.20] <0.001 
60 years 137.72 [137.03 ‒ 138.41]  146.72 [143.94 ‒ 149.49]  8.99 [6.20 ‒ 11.79] <0.001           
Diastolic blood 
pressure (mmHg)          
20 years 68.03 [67.50 ‒ 68.57]  71.49 [69.97 ‒ 73.02]  3.46 [1.95 ‒ 4.97] <0.001 
30 years 69.99 [69.75 ‒ 70.23]  75.15 [74.20 ‒ 76.10]  5.16 [4.20 ‒ 6.12] <0.001 
40 years 74.29 [74.09 ‒ 74.49]   78.63 [77.71 ‒ 79.54]   4.33 [3.40 ‒ 5.27]  <0.001 
50 years 78.61 [78.35 ‒ 78.87]  83.82 [82.66 ‒ 84.98]  5.21 [4.03 ‒ 6.38] <0.001 
60 years 79.86 [79.43 ‒ 80.30]  82.68 [80.91 ‒ 84.45]  2.82 [1.03 ‒ 4.60]   0.002           
BMI (kg/m2)          
20 years 22.78 [22.69 ‒ 22.86]  23.82 [23.61 ‒ 24.04]  1.05 [0.84 ‒ 1.26] <0.001 
30 years 23.92 [23.83 ‒ 24.00]  26.25 [25.95 ‒ 26.56]  2.34 [2.03 ‒ 2.65] <0.001 
40 years 24.89 [24.81 ‒ 24.97]   26.97 [26.64 ‒ 27.30]   2.08 [1.75 ‒ 2.41]  <0.001 
50 years 25.92 [25.81 ‒ 26.03]  28.36 [27.95 ‒ 28.77]  2.44 [2.03 ‒ 2.85] <0.001 
60 years 26.62 [26.45 ‒ 26.79]  29.01 [28.44 ‒ 29.58]  2.39 [1.82 ‒ 2.96] <0.001           
Waist circumference 
(cm)          
20 years 77.08 [76.39 ‒ 77.78]  79.82 [77.93 ‒ 81.72]  2.74 [0.86 ‒ 4.62]  0.004 
30 years 81.79 [81.44 ‒ 82.13]  86.88 [85.67 ‒ 88.10]  5.09 [3.86 ‒ 6.33] <0.001 
40 years 83.35 [83.11 ‒ 83.60]   87.99 [86.92 ‒ 89.06]   4.64 [3.55 ‒ 5.73]  <0.001 
50 years 85.37 [85.10 ‒ 85.63]  90.49 [89.28 ‒ 91.69]  5.12 [3.89 ‒ 6.35] <0.001 
60 years 86.69 [86.26 ‒ 87.11]  90.43 [88.72 ‒ 92.13]  3.74 [2.02 ‒ 5.46] <0.001           
Hip circumference 
(cm)          
20 years 97.98 [97.35 ‒ 98.60]  98.91 [97.19 ‒ 100.63]  0.93 [-0.77 ‒ 2.63]   0.281 
30 years 100.80 [100.50 ‒ 101.09]  105.53 [104.49 ‒ 106.57]  4.73 [3.68 ‒ 5.79] <0.001 
40 years 101.88 [101.68 ‒ 102.07]   105.15 [104.29 ‒ 106.02]   3.28 [2.40 ‒ 4.16]  <0.001 
50 years 102.83 [102.63 ‒ 103.04]  106.03 [105.10 ‒ 106.97]  3.20 [2.25 ‒ 4.15] <0.001 
60 years 102.72 [102.40 ‒ 103.04]  105.09 [103.79 ‒ 106.38]  2.37 [1.06 ‒ 3.67] <0.001           
Waist to hip ratio          
20 years 0.78 [0.78 ‒ 0.79]  0.80 [0.79 ‒ 0.81]  0.02 [0.01 ‒ 0.03]   0.001 
30 years 0.81 [0.81 ‒ 0.81]  0.82 [0.82 ‒ 0.83]  0.01 [0.01 ‒ 0.02]   0.001 
40 years 0.82 [0.81 ‒ 0.82]   0.83 [0.83 ‒ 0.84]   0.02 [0.01 ‒ 0.02]  <0.001 
50 years 0.83 [0.83 ‒ 0.83]  0.85 [0.84 ‒ 0.86]  0.02 [0.01 ‒ 0.03] <0.001 
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*Linear predictions are estimated with all covariates set at their means and as if the woman has her first birth at age 23. 
†CRP is given as geometric mean values where the difference equates to the ratio of geometric mean CRP between 





Table S2 continued. Predicted mean levels of cardiovascular disease risk factors by age at follow-up in women with 
normotensive and preeclamptic first pregnancies. 
 Normotensive  Preeclampsia  Difference 
Linear prediction* estimate 95% CI   estimate 95% CI   estimate 95% CI p-value 
Non-HDL cholesterol 
(mmol/L)          
20 years 3.18 [3.11 ‒ 3.24]  3.42 [3.22 ‒ 3.61]  0.24 [0.05 ‒ 0.43]   0.013 
1st birth occurs at age 23 
30 years 3.40 [3.37 ‒ 3.44]  3.64 [3.52 ‒ 3.76]  0.24 [0.11 ‒ 0.36] <0.001 
40 years 3.72 [3.70 ‒ 3.74]   3.88 [3.78 ‒ 3.99]   0.16 [0.05 ‒ 0.27]     0.003 
50 years 4.31 [4.29 ‒ 4.34]  4.42 [4.30 ‒ 4.54]  0.11 [-0.01 ‒ 0.23] 0.073 
60 years 4.77 [4.73 ‒ 4.81]  4.73 [4.56 ‒ 4.90]  -0.04 [-0.21 ‒ 0.13] 0.663 
          
HDL cholesterol 
(mmol/L)          
20 years 1.43 [1.41 ‒ 1.46]  1.44 [1.38 ‒ 1.51]  0.01 [-0.05 ‒ 0.08] 0.724 
30 years 1.39 [1.38 ‒ 1.40]  1.32 [1.28 ‒ 1.36]  -0.07 [-0.11 ‒ -0.03] 0.001 
40 years 1.43 [1.42 ‒ 1.44]   1.37 [1.34 ‒ 1.41]   -0.06 [-0.10 ‒ -0.03]  0.001 
50 years 1.53 [1.52 ‒ 1.54]  1.50 [1.46 ‒ 1.54]  -0.03 [-0.07 ‒ 0.01] 0.175 
60 years 1.55 [1.54 ‒ 1.56]  1.55 [1.49 ‒ 1.60]  0.00 [-0.06 ‒ 0.05] 0.923           
Triglycerides (mmol/L)          
20 years 1.22 [1.170 ‒ 1.269]  1.40 [1.266 ‒ 1.540]  0.18 [0.05 ‒ 0.32] 0.008 
30 years 1.16 [1.13 ‒ 1.18]  1.29 [1.188 ‒ 1.384]  0.13 [0.03 ‒ 0.23] 0.011 
40 years 1.23 [1.21 ‒ 1.25]   1.39 [1.30 ‒ 1.48]   0.16 [0.06 ‒ 0.25]  0.001 
50 years 1.45 [1.42 ‒ 1.47]  1.58 [1.48 ‒ 1.69]  0.14 [0.03 ‒ 0.24] 0.009 
60 years 1.67 [1.63 - 1.70]  1.70 [1.55 - 1.86]  0.04 [-0.12 ‒ 0.19] 0.649 
          
Glucose (mmol/L)          
20 years 4.87 [4.79 ‒ 4.95]  5.07 [4.85 ‒ 5.28]  0.20 [-0.01 ‒ 0.41] 0.068 
30 years 4.89 [4.85 ‒ 4.93]  5.07 [4.94 ‒ 5.20]  0.18 [0.04 ‒ 0.32] 0.010 
40 years 5.12 [5.09 ‒ 5.15]   5.19 [5.07 ‒ 5.31]   0.07 [-0.05 ‒ 0.19]  0.268 
50 years 5.32 [5.29 ‒ 5.35]  5.47 [5.32 ‒ 5.61]  0.14 [-0.00 ‒ 0.29] 0.052 
60 years 5.58 [5.53 ‒ 5.63]  5.80 [5.56 ‒ 6.04]  0.22 [-0.02 ‒ 0.46] 0.076           
Resting heart rate 
(beats/min)          
20 years 75.07 [74.38 ‒ 75.76]  77.45 [75.48 ‒ 79.42]  2.38 [0.42 ‒ 4.33] 0.017 
30 years 73.90 [73.60 ‒ 74.20]  74.94 [73.74 ‒ 76.13]  1.03 [-0.18 ‒ 2.25] 0.095 
40 years 73.63 [73.38 ‒ 73.87]   74.56 [73.45 ‒ 75.67]   0.93 [-0.20 ‒ 2.06]  0.105 
50 years 72.96 [72.65 ‒ 73.27]  74.26 [72.88 ‒ 75.64]  1.30 [-0.10 ‒ 2.70] 0.068 
60 years 73.12 [72.61 ‒ 73.63]  71.50 [69.39 ‒ 73.62]  -1.61 [-3.75 ‒ 0.53] 0.139 
          
CRP† (mg/L)          
20 years 1.69 [1.45 ‒ 1.97]  1.69 [1.08 ‒ 2.63]  1.00 [0.64 ‒ 1.56] 0.997 
30 years 1.00 [0.93 ‒ 1.07]  1.15 [0.89 ‒ 1.49]  1.15 [0.88 ‒ 1.50] 0.297 
40 years 0.81 [0.78 ‒ 0.85]   1.05 [0.89 ‒ 1.23]   1.29 [1.09 ‒ 1.53]  0.003 
50 years 0.96 [0.92 ‒ 1.00]  1.25 [1.04 ‒ 1.49]  1.30 [1.08 ‒ 1.56] 0.005 
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Table S3. Predicted change in cardiovascular disease risk factor level from pre- to post-first pregnancy in women with 
normotensive or preeclamptic first pregnancy. 
  Normotension   Preeclampsia   Difference 
  Change 95 % CI   Change 95 % CI   Change 95 % CI p-value 
Systolic blood pressure (mmHg) -3.81 [-4.65 ‒ -2.97]  -2.99 [-5.32 ‒ -0.67 ]  0.82 [-1.47 ‒ 3.11] 0.485 
Diastolic blood pressure (mmHg) -2.17 [-2.81 ‒ -1.53]  -0.44 [-2.17 ‒ 1.29 ]  1.72 [0.03 ‒ 3.42] 0.046 
BMI (kg/m2) 0.03 [-0.08 ‒ 0.15]  0.95 [0.51 ‒ 1.40 ]  0.92 [0.46 ‒ 1.37] <0.001 
Waist circumference (cm) 3.06 [2.19 ‒ 3.93]  5.21 [2.86 ‒ 7.57 ]  2.15 [-0.17 ‒ 4.47] 0.070 
Hip circumference (cm) 1.03 [0.24 ‒ 1.81]  2.29 [0.21 ‒ 4.38 ]  1.27 [-0.78 ‒ 3.31] 0.226 
Waist to hip ratio 0.02 [0.02 ‒ 0.03]  0.03 [0.01 ‒ 0.04 ]  0.00 [-0.01 ‒ 0.02] 0.549 
Non-HDL cholesterol (mmol/L) -0.02 [-0.10 ‒ 0.07]  0.09 [-0.14 ‒ 0.33 ]  0.11 [-0.12 ‒ 0.34] 0.363 
HDL cholesterol (mmol/L) -0.14 [-0.17 ‒ -0.11]  -0.11 [-0.19 ‒ -0.03 ]  0.02 [-0.06 ‒ 0.10] 0.567 
Triglycerides (mmol/L) 0.01 [-0.06 ‒ 0.07]  0.05 [-0.12 ‒ 0.23 ]  0.04 [-0.13 ‒ 0.22] 0.614 
Glucose (mmol/L) -0.10 [-0.20 ‒ -0.01]  -0.32 [-0.58 ‒ -0.07 ]  -0.22 [-0.47 ‒ 0.03] 0.090 
Resting heart rate (beats/min) 0.94 [0.11 ‒ 1.77]  0.44 [-1.77 ‒ 2.65 ]  -0.50 [-2.66 ‒ 1.66] 0.649 
CRP* (mg/L) 0.85 [0.69 ‒ 1.05]   0.79 [0.45 ‒ 1.39 ]   0.93 [0.53 ‒ 1.63] 0.797 
*CRP is given as geometric mean values where the difference equates to the ratio of geometric mean CRP between women with 
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Table S4. Predicted change per year in cardiovascular disease risk factors by age interval in women with normotensive 
and preeclamptic first pregnancies.  
Change per year 
Normotension   Preeclampsia     Difference   
estimate 95% CI   estimate 95% CI   estimate 95% CI p-value 
Systolic blood pressure 
(mmHg/year)          
20-23 years 0.09 [-0.04 ‒ 0.22]  0.38 [0.03 ‒ 0.73]   0.29 [-0.05 ‒ 0.63]  0.097 
23-30 years 0.21 [0.12 ‒ 0.30]  0.09 [-0.25 ‒ 0.43]  -0.12 [-0.46 ‒ 0.23]  0.500 
30-40 years 0.43 [0.37 ‒ 0.50]  0.41 [0.21 ‒ 0.61]   0.00 [-0.21 ‒0.20]  0.981 
40-50 years 0.84 [0.79 ‒ 0.89]  1.15 [0.93 ‒ 1.36]   0.33 [0.11 ‒ 0.54]  0.004 
50-60 years 0.84 [0.77 ‒ 0.91]  0.80 [0.50 ‒ 1.11]   -0.04 [-0.35 ‒ 0.27]  0.811 
          
Diastolic blood pressure 
(mmHg/year)          
20-23 years 0.44 [0.34 ‒ 0.54]  0.62 [0.36 ‒ 0.87]   0.17 [-0.07 ‒ 0.42]  0.170 
23-30 years 0.40 [0.33 ‒ 0.47]  0.31 [0.06 ‒ 0.56]  -0.09 [-0.34 ‒ 0.16]  0.489 
30-40 years 0.44 [0.39 ‒ 0.48]  0.35 [0.21 ‒ 0.49]   -0.08 [-0.22  ‒ 0.06]  0.249 
40-50 years 0.44 [0.41 ‒ 0.47]  0.52 [0.38 ‒ 0.66]   0.09 [-0.06  ‒ 0.23]  0.239 
50-60 years 0.13 [0.08 ‒ 0.17]  -0.11 [-0.32 ‒ 0.09]   -0.24 [-0.45  ‒ -0.03]  0.023 
          
BMI (kg/m2/year)          
18-23 years 0.08 [0.06 ‒ 0.10]  0.16 [0.11 ‒ 0.20]   0.08 [0.03 ‒ 0.12]  0.001 
23-30 years 0.13 [0.11 ‒ 0.14]  0.14 [0.09 ‒ 0.20]  0.02 [-0.03 ‒ 0.07]  0.502 
30-40 years 0.10 [0.09 ‒ 0.12]  0.07 [0.04 ‒ 0.11]   -0.03 [-0.06  ‒ 0.01]  0.151 
40-50 years 0.10 [0.09 ‒ 0.11]  0.14 [0.10 ‒ 0.17]   0.04 [-0.00  ‒ 0.07]  0.052 
50-60 years 0.07 [0.06 ‒ 0.08]  0.07 [0.02 ‒ 0.12]   0.00 [-0.06  ‒ 0.05]  0.850 
          
Waist circumference 
(cm/year)          
20-23 years 0.17 [0.05 ‒ 0.29]  0.30 [-0.02 ‒ 0.62]   0.13 [-0.18 ‒ 0.45]  0.401 
23-30 years 0.16 [0.06 ‒ 0.26]  0.13 [-0.19 ‒ 0.44]  -0.03 [-0.35 ‒ 0.28]  0.835 
30-40 years 0.18 [0.12 ‒ 0.23]  0.11 [-0.05 ‒ 0.27]   -0.05 [-0.21 ‒ 0.11]  0.576 
40-50 years 0.18 [0.15 ‒ 0.21]  0.25 [0.10 ‒ 0.39]   0.05 [-0.10 ‒ 0.20]  0.522 
50-60 years 0.13 [0.09 ‒ 0.17]  -0.01 [-0.18 ‒ 0.17]   -0.14 [-0.32 ‒ 0.04]  0.135           
Hip circumference 
(cm/year)          
20-23 years 0.18 [0.07 ‒ 0.28]  0.48 [0.21 ‒ 0.76]   0.31 [0.04 ‒ 0.58]  0.027 
23-30 years 0.18 [0.10 ‒ 0.26]  0.41 [0.14 ‒ 0.68]  0.23 [-0.05 ‒ 0.50]  0.105 
30-40 years 0.13 [0.09 ‒ 0.18]  -0.04 [-0.17 ‒ 0.09]   -0.15 [-0.28 ‒ -0.01]  0.032 
40-50 years 0.09 [0.06 ‒ 0.12]  0.09 [-0.03 ‒ 0.21]   -0.01 [-0.13 ‒ 0.11]  0.899 
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*CRP is given as geometric mean values where the difference equates to the ratio of geometric mean CRP between 
women with preeclampsia and normotensive women.   
Table S4 continued. Predicted change per year in cardiovascular disease risk factors by age interval in women with 
normotensive and preeclamptic first pregnancies.   
 Normotension   Preeclampsia   Difference 
Change per year estimate 95% CI   estimate 95% CI   estimate 95% CI p-value 
Non-HDL cholesterol 
(mmol/L/year)          
20-23 years 0.03 [0.02 ‒ 0.04]  0.02 [-0.01 ‒ 0.05]   -0.01 [-0.04 ‒ 0.02]  0.647 
23-30 years 0.02 [0.01 ‒ 0.03]  0.01 [-0.02 ‒ 0.04]  -0.01 [-0.05 ‒ 0.02]  0.442 
30-40 years 0.03 [0.02 ‒ 0.04]  0.02 [0.01 ‒ 0.04]   -0.01 [-0.02 ‒ 0.01]  0.410 
40-50 years 0.06 [0.06 ‒ 0.06]  0.05 [0.04 ‒ 0.07]   -0.01 [-0.02 ‒ 0.01]  0.514 
50-60 years 0.05 [0.04 ‒ 0.05]  0.03 [0.01 ‒ 0.05]   -0.01 [-0.03 ‒ 0.01]  0.150           
HDL cholesterol 
(mmol/L/year)          
20-23 years 0.01 [0.01 ‒ 0.02]  0.00 [-0.01 ‒ 0.01]   -0.01 [-0.02 ‒ -0.00]  0.024 
23-30 years 0.01 [0.01 ‒ 0.01]  0.00 [-0.01 ‒ 0.01]  -0.01 [-0.02 ‒ 0.00]  0.085 
30-40 years 0.00 [0.00 ‒ 0.01]  0.00 [-0.00 ‒ 0.01]   0.00 [-0.00 ‒ 0.01]  0.780 
40-50 years 0.01 [0.01 ‒ 0.01]  0.01 [0.01 ‒ 0.02]   0.00 [-0.00 ‒ 0.01]  0.176 
50-60 years 0.00 [0.00 ‒ 0.00]  0.00 [-0.00 ‒ 0.01]   0.00 [-0.00 ‒ 0.01]  0.428           
Triglycerides 
(mmol/L/year)          
20-23 years -0.01 [-0.02 ‒ -0.00]  -0.01 [-0.04 ‒ 0.01]   0.00 [-0.03 ‒ 0.02]  0.884 
23-30 years -0.01 [-0.01 ‒ 0.00]  -0.02 [-0.04 ‒ 0.01]  -0.01 [-0.04 ‒ 0.01]  0.283 
30-40 years 0.01 [0.00 ‒ 0.01]  0.01 [-0.00 ‒ 0.02]   0.00 [-0.01 ‒ 0.02]  0.708 
40-50 years 0.02 [0.02 ‒ 0.02]  0.02 [0.01 ‒ 0.03]   0.00 [-0.02 ‒ 0.01]  0.804 
50-60 years 0.02 [0.02 ‒ 0.03]  0.01 [-0.01 ‒ 0.03]   -0.01 [-0.03 ‒ 0.01]  0.274           
Glucose (mmol/L/year)          
20-23 years 0.01 [-0.00 ‒ 0.03]  0.03 [-0.00 ‒ 0.07]   0.02 [-0.01 ‒ 0.06]  0.238 
23-30 years 0.01 [0.00 ‒ 0.02]  0.03 [-0.01 ‒ 0.07]  0.02 [-0.02 ‒ 0.06]  0.319 
30-40 years 0.02 [0.02 ‒ 0.03]  0.01 [-0.01 ‒ 0.03]   -0.01 [-0.03 ‒ 0.01]  0.286 
40-50 years 0.02 [0.02 ‒ 0.02]  0.03 [0.01 ‒ 0.05]   0.01 [-0.01 ‒ 0.03]  0.469 
50-60 years 0.03 [0.02 ‒ 0.03]  0.03 [0.01 ‒ 0.06]   0.01 [-0.02 ‒ 0.04]  0.609           
Resting heart rate 
(beats/min/year)          
20-23 years -0.13 [-0.26 ‒ -0.01]  -0.12 [-0.44 ‒ 0.21]   0.02 [-0.30 ‒ 0.33]  0.920 
23-30 years -0.25 [-0.33 ‒ -0.16]  -0.38 [-0.69 ‒ -0.07]  -0.13 [-0.45 ‒ 0.18]  0.409 
30-40 years -0.01 [-0.07 ‒ 0.04]  -0.04 [-0.21 ‒ 0.13]   -0.01 [-0.18 ‒ 0.16]  0.909 
40-50 years -0.07 [-0.11 ‒ -0.03]  -0.03 [-0.21 ‒ 0.15]   0.04 [-0.14 ‒ 0.22]  0.687 
50-60 years 0.02 [-0.04 ‒ 0.07]  -0.28 [-0.53 ‒ -0.02]   -0.29 [-0.55 ‒ -0.04]  0.026           
CRP* (mg/L/year)          
20-23 years          
23-30 years 0.97 [0.94 ‒ 1.00]  1.01 [0.93 ‒ 1.09]   1.04 [0.97 ‒ 1.12]  0.296 
30-40 years 0.96 [0.94 ‒ 0.99]  0.98 [0.91 ‒ 1.05]  1.01 [0.94 ‒ 1.09]  0.725 
40-50 years 0.98 [0.97 ‒ 0.99]  0.99 [0.96 ‒ 1.02]   1.01 [0.98  ‒ 1.05]  0.503 




 http://ahajournals.org by on September 17, 2018
   
Table S5. Population average predicted probabilities* of hypertension, obesity and diabetes by age at follow-up 
in women with normotension, preeclampsia and gestational hypertension in first pregnancy. 
 First pregnancy 
 Normotension  Preeclampsia 
 Gestational hypertension 
Age probability 95% CI   probability 95% CI  probability 95% CI 
Hypertension      
   
20 years 0.05 [0.04 ‒ 0.06]  0.15 [0.10 ‒ 0.23] 
 0.15 [0.07 ‒ 0.29] 
30 years 0.05 [0.04 ‒ 0.06]  0.13 [0.10 ‒ 0.17] 
 0.25 [0.18 ‒ 0.32] 
40 years 0.13 [0.12 ‒ 0.13]   0.31 [0.26 ‒ 0.36]  
 0.34 [0.28 ‒ 0.41]  
50 years 0.34 [0.32 ‒ 0.35]  0.55 [0.49 ‒ 0.62] 
 0.52 [0.43 ‒ 0.60] 
60 years 0.58 [0.55 ‒ 0.60]  0.78 [0.70 ‒ 0.84] 
 0.79 [0.69 ‒ 0.87] 
         
Obesity      
   
20 years 0.03 [0.02 , 0.03]  0.07 [0.04 , 0.10] 
 0.06 [0.03 , 0.11] 
30 years 0.07 [0.06 , 0.08]  0.17 [0.13 , 0.21] 
 0.18 [0.13 , 0.25] 
40 years 0.08 [0.08 , 0.09]   0.16 [0.13 , 0.20]  
 0.20 [0.16 , 0.26]  
50 years 0.09 [0.08 , 0.10]  0.17 [0.13 , 0.21] 
 0.21 [0.15 , 0.28] 
60 years 0.11 [0.10 , 0.13]  0.18 [0.12 , 0.24] 
 0.21 [0.13 , 0.31] 
         
Diabetes              
   
20 years 0.003 [0.001 ‒ 0.009]  0.02 [0.00 ‒ 0.06] 
 0.000 [0.00 ‒ 0.000] 
30 years 0.004 [0.002 ‒ 0.006]  0.01 [0.00 ‒ 0.02] 
 0.015 [0.002 ‒ 0.10] 
40 years 0.01 [0.01 ‒ 0.01]   0.02 [0.01 ‒ 0.04]  
 0.002 [0.000 ‒ 0.02]  
50 years 0.01 [0.01 ‒ 0.02]  0.04 [0.02 ‒ 0.06] 
 0.02 [0.01 ‒ 0.05] 
60 years 0.03 [0.02 ‒ 0.04]   0.06 [0.03 ‒ 0.12]  0.10 [0.05 ‒ 0.21] 
*Population average proportions are estimated with all covariates set at their means and as if the woman has her first 





 http://ahajournals.org by on September 17, 2018










 http://ahajournals.org by on September 17, 2018
Figure S2. Life course trajectories of mean systolic blood pressure (a), diastolic blood pressure (b), BMI (c), waist 
circumference (d), hip circumference (e) and waist to hip ratio (f) for women with normotension and gestational 
hypertension in their first pregnancies. 
 
 
Estimates are adjusted for age at measurement, HUNT survey, highest obtained education level, age at first birth and ever 
daily smoking. Covariates are fixed at their means with gaps in the graphs corresponding to the woman’s first pregnancy, 
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Figure S3. Life course trajectories of mean non-fasting non-HDL (a) and HDL (b) cholesterol, triglycerides (c), 
and glucose (d), resting heart rate (e), and serum CRP (f) for women with normotension and gestational 
hypertension in their first pregnancies. 
 
Estimates are adjusted for age at measurement, HUNT survey, highest obtained education level, age at first pregnancy 
and ever daily smoking. Analyses of glucose and triglycerides were additionally adjusted for time since last meal. 
Covariates are fixed at their means with gaps in the graphs corresponding to the woman’s first pregnancy, birth at age 23 
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Figure S4. Life course trajectories of mean estimated glomerular filtration rate (eGFR) for women with 
normotension, preeclampsia (a) or gestational hypertension (b) in their first pregnancies. 
 
Estimates are adjusted for age at measurement, HUNT survey, highest obtained education level, age at first pregnancy 
and ever daily smoking. Covariates are fixed at their means with gaps in the graphs corresponding to the woman’s first 





 http://ahajournals.org by on September 17, 2018
Figure S5. Life course trajectories of mean systolic blood pressure (a), diastolic blood pressure (b), BMI (c), waist 
circumference (d), hip circumference (e) and waist to hip ratio (f) for women with normotensive and preeclamptic 
first pregnancies who had two or more observations. 
 
Estimates are adjusted for age at measurement, HUNT survey, highest obtained education level, age at first pregnancy 
and ever daily smoking. Covariates are fixed at their means with gaps in the graphs corresponding to the woman’s first 
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Figure S6. Life course trajectories of mean non-fasting serum non-HDL (a) and HDL (b) cholesterol, 
triglycerides (c) and glucose (d), resting heart rate (e), and estimated glomerular filtration rate (f) for 
women with normotensive and preeclamptic first pregnancies who had two or more observations. 
 
Estimates are adjusted for age at measurement, HUNT survey, highest obtained education level, age at first pregnancy 
and ever daily smoking. Covariates are fixed at their means with gaps in the graphs corresponding to the woman’s first 
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Figure S7. Life course trajectories of mean systolic blood pressure (a), diastolic blood pressure (b), BMI (c), waist 
circumference (d), hip circumference (e) and waist to hip ratio (f) for women with normotensive first and second 
pregnancy, preeclampsia in one of their first two pregnancies and preeclampsia in both the first and second 
pregnancy.   
 
Estimates are adjusted for age at measurement, HUNT survey, time between first and second pregnancy, highest obtained education 
level, age at first pregnancy and ever daily smoking. Covariates are fixed at their means with gaps in the graphs corresponding to the 
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Figure S8. Life course trajectories of mean non-fasting serum non-HDL (a) and HDL (b) cholesterol, triglycerides (c) and 
glucose (d), resting heart rate (e) and serum CRP (f) for women with normotensive first and second pregnancy, preeclampsia 
in one of their first two pregnancies and preeclampsia in both the first and second pregnancy.   
 
Estimates are adjusted for age at measurement, HUNT survey, time between first and second pregnancy, highest obtained education 
level, age at first pregnancy and ever daily smoking. Covariates are fixed at their means with gaps in the graphs corresponding to the 
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Figure S9. Life course trajectories of mean estimated glomerular filtration rate (eGFR) for women with 
normotensive first and second pregnancy, preeclampsia in one of their first two pregnancies and preeclampsia in 
both the first and second pregnancy.   
 
 
Estimates are adjusted for age at measurement, HUNT survey, time between first and second pregnancy, highest obtained 
education level, age at first pregnancy and ever daily smoking. Covariates are fixed at their means with gaps in the 
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Figure S10. Population average predicted probabilities of hypertension (defined as current antihypertensive 
medication and/or blood pressure ≥140 mmHg systolic or ≥90 mmHg diastolic) (a) and obesity (defined as a BMI 
≥30 kg/m2) (b) by age in women with normotensive 1st and 2nd pregnancy, preeclampsia in one of their first two 
pregnancies and preeclampsia in both the 1st and 2nd pregnancy. 
 
Estimates are adjusted for age at measurement, HUNT survey, time between 1st and 2nd pregnancy, highest obtained 
education level, age at first birth and ever daily smoking. Covariates are fixed at their means with gaps in the graphs 
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